No Data
No Data
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $1.2
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
Lexicon Pharmaceuticals: Strategic Focus on Promising Pipeline Amid Clinical Progress and Restructuring
Express News | Lexicon Pharmaceuticals Inc - Top-Line Data From Progress Study Expected in Q1 2025
Express News | Lexicon Announces Completion of Enrollment in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)